<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>UMBRALISIB - Research Report</title>
    <meta name="description" content="Comprehensive naturopathic research report for UMBRALISIB">
    <style>
        
    * {
        box-sizing: border-box;
    }
    
    body {
        font-family: 'Segoe UI', 'Helvetica Neue', Arial, sans-serif;
        font-size: 16px;
        line-height: 1.6;
        margin: 0;
        padding: 0;
        background-color: #f8f9fa;
        color: #212529;
    }
    
    .container {
        max-width: 1200px;
        margin: 0 auto;
        padding: 20px;
        background-color: white;
        box-shadow: 0 0 10px rgba(0,0,0,0.1);
    }
    
    .medication-header {
        background: linear-gradient(135deg, #2c3e50, #003366);
        color: white;
        padding: 30px;
        margin: -20px -20px 30px -20px;
        border-radius: 0 0 10px 10px;
        text-align: center;
        position: relative;
    }
    
    .medication-header h1 {
        margin: 0 0 15px 0;
        font-size: 2.5em;
        font-weight: 600;
        text-shadow: 0 2px 4px rgba(0,0,0,0.3);
    }
    
    .status-badge {
        display: inline-block;
        padding: 8px 20px;
        border-radius: 25px;
        font-weight: 600;
        font-size: 0.9em;
        text-transform: uppercase;
        letter-spacing: 1px;
        box-shadow: 0 2px 4px rgba(0,0,0,0.2);
    }
    
    .status-allowed { background-color: #28a745; color: white; }
    .status-not-allowed { background-color: #dc3545; color: white; }
    .status-modernization { background-color: #fd7e14; color: white; }
    .status-topical { background-color: #20c997; color: white; }
    .status-review { background-color: #ffc107; color: #212529; }
    .status-not-applicable { background-color: #6c757d; color: white; }
    .status-unknown { background-color: #adb5bd; color: white; }
    
    .natural-connections {
        margin-bottom: 30px;
        padding: 20px;
        background-color: #f8f9fa;
        border-radius: 10px;
        border-left: 4px solid #007bff;
    }
    
    .natural-connections h2 {
        margin: 0 0 15px 0;
        font-size: 1.4em;
        color: #2c3e50;
    }
    
    .connection-tags {
        display: flex;
        flex-wrap: wrap;
        gap: 8px;
    }
    
    .connection-tag {
        display: inline-block;
        padding: 6px 12px;
        border-radius: 15px;
        font-size: 0.85em;
        font-weight: 500;
        color: white;
        white-space: nowrap;
    }
    
    .tag-direct { background-color: #0d6832; }
    .tag-semi-synthetic { background-color: #198754; }
    .tag-structural { background-color: #0d6efd; }
    .tag-endogenous { background-color: #6610f2; }
    .tag-biosynthetic { background-color: #6f42c1; }
    .tag-pathways { background-color: #0dcaf0; color: #212529; }
    .tag-processes { background-color: #3dd5f3; color: #212529; }
    
    .report-content {
        line-height: 1.7;
    }
    
    .report-content h1 {
        color: #2c3e50;
        border-bottom: 3px solid #007bff;
        padding-bottom: 10px;
        margin: 30px 0 20px 0;
    }
    
    .report-content h2 {
        color: #495057;
        border-bottom: 2px solid #dee2e6;
        padding-bottom: 8px;
        margin: 25px 0 15px 0;
    }
    
    .report-content h3 {
        color: #6c757d;
        margin: 20px 0 10px 0;
    }
    
    .report-content p {
        margin-bottom: 15px;
        text-align: justify;
    }
    
    .checkbox {
        font-weight: bold;
        margin-right: 5px;
    }
    
    .checkbox.checked { color: #28a745; }
    .checkbox.unchecked { color: #6c757d; }
    
    .footer {
        margin-top: 40px;
        padding: 20px 0;
        border-top: 1px solid #dee2e6;
        text-align: center;
        color: #6c757d;
        font-size: 0.9em;
    }
    
    .back-link {
        display: inline-block;
        margin-bottom: 20px;
        padding: 8px 16px;
        background-color: #007bff;
        color: white;
        text-decoration: none;
        border-radius: 5px;
        transition: background-color 0.3s;
    }
    
    .back-link:hover {
        background-color: #0056b3;
        text-decoration: none;
    }
    
    @media (max-width: 768px) {
        .container { 
            padding: 15px; 
            margin: 10px;
        }
        .medication-header { 
            margin: -15px -15px 20px -15px;
            padding: 20px;
        }
        .medication-header h1 { 
            font-size: 2em; 
        }
        .connection-tags {
            justify-content: center;
        }
    }
    
    @media print {
        .back-link { display: none; }
        .container { box-shadow: none; }
        .medication-header { 
            background: #2c3e50 !important;
            -webkit-print-color-adjust: exact;
        }
    }
    
    </style>
</head>
<body>
    <div class="container">
        <a href="index.html" class="back-link">← Back to Index</a>
        
        <header class="medication-header">
            <h1>UMBRALISIB</h1>
            <div class="status-badge status-not-allowed">
                NOT_ALLOWED
            </div>
        </header>
        
        <section class="natural-connections">
            <h2>Natural Connections</h2>
            <div class="connection-tags">
                <span class="connection-tag tag-pathways">Works Natural Pathways</span>
<span class="connection-tag tag-processes">Facilitates Natural Processes</span>

            </div>
        </section>
        
        <main class="report-content">
            <h2>1. NATURAL DERIVATION ASSESSMENT</h2>
<h3>Source Investigation</h3>
UMBRALISIB works through naturally occurring biological pathways and receptor systems. It was developed for therapeutic use in plants, animals, fungi, minerals, or marine organisms. There is no documented historical use in traditional medicine systems, and it is not produced via fermentation or biosynthetic methods. Umbralisib was developed through rational drug design as a dual inhibitor targeting specific kinases.
<h3>Structural Analysis</h3>
Umbralisib is structurally classified as a pyrazolo[3,4-d]pyrimidine derivative. While this synthetic scaffold does not directly mirror naturally occurring compounds, the molecule contains functional groups (pyrazole and pyrimidine rings) that are found in some natural products and nucleotide bases. The compound does not structurally resemble endogenous human compounds, though it targets proteins that interact with naturally occurring signaling molecules.
<h3>Biological Mechanism Evaluation</h3>
Umbralisib functions as a dual inhibitor of phosphoinositide 3-kinase delta (PI3Kδ) and casein kinase-1 epsilon (CK1ε). These kinases are naturally occurring enzymes involved in cellular signaling pathways. PI3Kδ plays a crucial role in B-cell receptor signaling and immune cell activation, while CK1ε is involved in Wnt signaling and circadian rhythm regulation. The drug works by binding to the ATP-binding sites of these endogenous enzymes, modulating natural cellular processes.
<h3>Natural System Integration (Expanded Assessment)</h3>
Umbralisib targets naturally occurring enzymes that are evolutionarily conserved across species and integral to normal physiological processes. By inhibiting PI3Kδ, it modulates B-cell activation and immune responses through naturally existing pathways. The inhibition of CK1ε affects endogenous Wnt signaling cascades. While the compound itself is synthetic, it integrates with natural immune regulatory systems and may help restore homeostatic balance in cases of aberrant B-cell proliferation. The medication works within established cellular signaling networks rather than creating entirely artificial biological effects.
<h2>2. THERAPEUTIC CONTEXT</h2>
<h3>Mechanism of Action</h3>
Umbralisib selectively inhibits PI3Kδ with greater than 1000-fold selectivity over other PI3K isoforms, and also inhibits CK1ε. This dual inhibition results in reduced B-cell receptor signaling, decreased cell proliferation, and induction of apoptosis in malignant B-cells. The mechanism leverages natural apoptotic pathways and cellular death mechanisms that are normally present but may be dysregulated in hematologic malignancies.
<h3>Clinical Utility</h3>
Umbralisib is FDA-approved for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) and follicular lymphoma (FL) who have received at least one prior anti-CD20-based regimen. The medication provides a targeted approach for patients with limited treatment options. Common adverse effects include diarrhea, fatigue, nausea, and elevated liver enzymes. The drug requires careful monitoring and is typically used as a temporary intervention to achieve disease control.
<h3>Integration Potential</h3>
As a targeted kinase inhibitor, umbralisib could potentially create therapeutic windows during which supportive naturopathic interventions might be implemented. However, its immunomodulatory effects and potential for significant adverse reactions require careful consideration. The medication&#x27;s role would likely be as a primary intervention for serious hematologic conditions, with naturopathic support focused on managing side effects and supporting overall health during treatment.
<h2>3. REGULATORY AND PRECEDENT CONTEXT</h2>
<h3>Current Status</h3>
Umbralisib received FDA accelerated approval in February 2021 but was subsequently withdrawn from the U.S. market in June 2022 due to safety concerns identified in post-marketing studies, including increased risk of death compared to standard treatments. The European Medicines Agency has not approved umbralisib. It is not included on the WHO Essential Medicines List.
<h3>Comparable Medications</h3>
Other PI3Kδ inhibitors such as idelalisib have faced similar regulatory challenges due to safety profiles. The class of kinase inhibitors represents a category not typically found in naturopathic formularies, though some formularies may include other targeted cancer therapies under specific circumstances.
<h2>4. EVIDENCE DOCUMENTATION</h2>
<h3>Primary Sources Consulted</h3>
Evidence was gathered from FDA prescribing information, DrugBank pharmaceutical database, PubChem chemical database, peer-reviewed publications on PI3K signaling pathways, and clinical trial literature. Additional information was obtained from regulatory communications regarding the drug&#x27;s withdrawal from market.
<h3>Key Findings</h3>
The compound is entirely synthetic with no direct natural derivation. However, it targets evolutionarily conserved enzymes involved in fundamental cellular processes. The drug&#x27;s mechanism relies on modulating natural apoptotic and signaling pathways. Safety concerns have led to market withdrawal, limiting its current therapeutic utility.
<h2>5. COMPREHENSIVE ASSESSMENT</h2>
<p><strong>UMBRALISIB</strong></p>
<p><strong>Evidence Categories Present:</strong><br><span class="checkbox unchecked">☐</span> Direct natural source<br><span class="checkbox unchecked">☐</span> Semi-synthetic from natural precursor<br><span class="checkbox unchecked">☐</span> Structural analog of natural compound<br><span class="checkbox unchecked">☐</span> Endogenous compound or replacement<br><span class="checkbox unchecked">☐</span> Biosynthetic/fermentation product<br><span class="checkbox checked">✓</span> Works through natural pathways/receptors<br><span class="checkbox unchecked">☐</span> Facilitates natural physiological processes<br><span class="checkbox unchecked">☐</span> No identified natural connection</p>
<p><strong>Natural Derivation Assessment:</strong><br>Umbralisib shows no direct natural derivation, being a laboratory-produced pharmaceutical compound developed through rational drug design. No natural occurrence or traditional medicine precedent exists for this molecule.</p>
<p><strong>Structural/Functional Relationships:</strong><br>While structurally synthetic, umbralisib contains pyrazole and pyrimidine functional groups that are present in some natural compounds and nucleotide bases. The molecule targets naturally occurring kinase enzymes that are evolutionarily conserved.</p>
<p><strong>Biological Integration:</strong><br>Umbralisib integrates with natural cellular signaling systems by inhibiting endogenous PI3Kδ and CK1ε enzymes. These targets are fundamental components of B-cell receptor signaling, Wnt pathways, and immune regulation systems that evolved naturally and are present across species.</p>
<p><strong>Natural System Interface:</strong><br>The medication works by modulating naturally occurring enzyme systems involved in cellular proliferation, apoptosis, and immune signaling. It targets proteins that normally interact with endogenous signaling molecules and are integral to physiological homeostasis.</p>
<p><strong>Safety and Therapeutic Profile:</strong><br>Significant safety concerns led to FDA market withdrawal in 2022 due to increased mortality risk compared to standard treatments. The drug showed efficacy in relapsed/refractory B-cell lymphomas but with an unfavorable risk-benefit profile.</p>
<p><strong>Documentation Quality:</strong><br>- Number of sources confirming natural connection: 0<br>- Number of sources documenting system integration: 5<br>- Strength of evidence: Limited (pharmaceutical compound with natural target systems)<br>- Conflicting information noted: No</p>
<p><strong>Summary of Findings:</strong><br>Umbralisib is a synthetic pharmaceutical compound with no direct natural derivation. However, it functions by targeting naturally occurring, evolutionarily conserved kinase enzymes that are integral to cellular signaling pathways. The drug&#x27;s withdrawal from market due to safety concerns significantly limits its therapeutic utility and appropriateness for formulary inclusion.</p>
<p><strong>Relevant Citations:</strong></p>
<p>1. DrugBank Online. &quot;Umbralisib&quot; DrugBank Accession Number DB12010. University of Alberta. Available at: https://go.drugbank.com/drugs/DB12010</p>
<p>2. PubChem. &quot;Umbralisib&quot; PubChem CID 46926350. National Center for Biotechnology Information, U.S. National Library of Medicine.</p>
<p>3. FDA. &quot;FDA grants accelerated approval to umbralisib for marginal zone lymphoma and follicular lymphoma.&quot; FDA News Release, February 5, 2021.</p>
<p>4. FDA. &quot;TG Therapeutics announces voluntary withdrawal of UKONIQ (umbralisib) from US market.&quot; FDA Safety Communication, June 29, 2022.</p>
<p>5. Burris HA 3rd, Flinn IW, Patel MR, et al. &quot;Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, multicentre, phase 1 trial.&quot; Lancet Oncology. 2018;19(4):486-496.</p>
<p>6. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. &quot;The emerging mechanisms of isoform-specific PI3K signalling.&quot; Nature Reviews Molecular Cell Biology. 2010;11(5):329-341.</p>
<p>7. Cheah CY, Fowler NH. &quot;Novel agents for relapsed and refractory follicular lymphoma.&quot; Best Practice &amp; Research Clinical Haematology. 2018;31(1):49-56.</p>
        </main>
        
        <footer class="footer">
            <p>Generated on September 12, 2025 at 12:39 PM</p>
        </footer>
    </div>
</body>
</html>